Who's Promised What: A Guide To Pharma Drug Pricing Pledges
Have pharma companies responded sufficiently to President Trump's call for “massive” price reductions?
You may also be interested in...
The idea could help quiet growing criticism over system gaming and high drug prices.
Presiding over his last earnings call as the CEO of Pfizer, Ian Read was pressed about the company's drug pricing strategy for 2019 amid push back from the Trump Administration.
“Authorized generics” for Gilead's leading hepatitis C brands stands out from prior, largely symbolic responses to the lower list prices. This is not a political move, but a business one. It is also the clearest demonstration yet of why pricing reforms are necessary if lower list prices are the policy goal.